Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRISPR-Cas9 PD-1/TCR KO anti-mesothelin CAR-T in Solid Tumors
NCT03545815Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2018
- Primary completion
- Oct 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-mesothelin CAR vector-transduced autologous T lymphocytes in solid tumor, sponsored by Chinese PLA General Hospital. Primary endpoint: Study of related adverse events at 24 weeks. Status: unknown.
02
Drugs
anti-mesothelin CAR vector-transduced autologous T lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03545815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545815.